Boletin General

 

COVID-19  / Abril - Mayo 2021


Annals of Internal Medicine

1. Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19.
2. The Reign of the Ventilator: Acute Respiratory Distress Syndrome, COVID-19, and Technological Imperatives in Intensive Care.
3. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.

Reviews 67(2021)

4. SARS CoV2 infection _The longevity study perspectives.

Biomedicine & Pharmacotherapy 136 (2021)

5. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines.
6. Human endeavor for anti-SARS-CoV-2 pharmacotherapy:A major strategy to fight the pandemic.
7. Effective drugs used  to combat SARS-CoV-2  infection and the current status of vaccines.
8. Target sand strategies for vaccine development against SARS-CoV-2.

BMC Infectious Diseases (2021)

9. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.

Cell Host & Microbe 29(2021)

10. The variant gam bit:COVID-19's next move

 European Journal of Medical Genetics 64(2021)

11. Why does SARS-CoV-2 hit in different ways? Host geneticf actors can influence the acquisition or the course of COVID-19.

Gene Reports 23(2021)

12. Mutations and polymorphisms in genes involved in the infections by covid19: a review.

Infection, Genetics and Evolution 90 (2021)

13. Variants in ACE2; potential influences on virus infectionand COVID-19 severity.

International Journal of Immunogenetics 48 (2)

14. A bioinformatic approach to investigating cytokine genes and their receptor variants in relation to COVID-19 progression.

JACC (Journal of the American College of Cardiology)

15. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19.
16. ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization.

Journal of Medical Virology 93

17. Analysis of SARS-CoV-2 mutations in Mexico, Belize, and isolated regions of Guatemala and its implication in the diagnosis.
18. Effects of SARS-CoV-2 mutations on protein structures and intraviral protein protein interactions.
19. Comparative insight into the genomic landscape of SARS-CoV-2 and identification of mutations associated with the origin of infection and diversity.
20. East West differences in clinical manifestations of COVID 19 patients: A systematic literature review and meta-analysis.

Lancet 397 (2021)

21. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
22. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform.

New England Journal of Medicine

23. BNT162b2 mRNA Covid-19 Vaccine in a Nation wide Mass Vaccination Setting.
24. Preparing for the Future - Nanobodies for Covid-19?.
25. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.

Nature

26. Spike mutation D614G alters SARS-CoV-2 fitness.
27.mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
28. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

Proteins 89 (5)

29. Human SARS CoV-2 spike protein mutations.

Trends in Genetics 37 (4)

30. Biosensing Detection of the SARS-CoV-2 D614G Mutation.